
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and has a diverse portfolio of products in areas such as pain treatments, surgical solutions, and restorative therapies. Despite a recent reimbursement cut for one of its products, Bioventus has maintained strong financial guidance for 2026, demonstrating management's confidence in the company's momentum. With a strong focus on investing in growth drivers and reducing debt, the company is poised for mid to high single-digit revenue growth and has potential for M&A opportunities in the future.
Bears say
Bioventus is facing a significant top-line headwind in FY/26, estimated to be around $2-3 million, primarily due to a recent Medicare reimbursement cut. While the company delivered strong Q4 results, with top-line revenue and profitability beating expectations, its restorative therapies segment showed a decline of 26.0%. Although management expects this segment to grow in 2026, the recent divestiture of the Advanced Rehab business and associated headwind distorts the results, and the company's overall growth outlook remains uncertain in the face of continued market challenges. Additionally, with a high level of debt and uncertain cash flows, there are concerns about the financial stability of Bioventus in the long term.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares